RankAlpha logo
Back to Rankings

PVLA

Palvella TherapeuticsD
Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
View Chart
+
Peers tracked
11
U.S. public peers
Grade Position
Below peers
vs peer average
PVLA vs peer average
33/100
PVLA vs. peer average (D vs. C)
Grade spread
A 3 · C 4 · D 3 · F 1
Graded peers loaded
Coverage
11 graded
100% of tracked

Peer overview

URGN is the first available peer comparator.

Useful specialty-biopharma comparator for a small company moving from development toward a focused commercial launch, though disease area overlap is limited.

✓Peer source comes from the stored AI memo or peer model
✓Grades and factor rows use RankAlpha API data when available
✓Missing peer scores remain blank instead of being estimated
✓Side-by-side comparison keeps the data contract visible
Top peerURGNUroGen
PVLA
Palvella Therapeutics
URGN
UroGen
Grade
D
F
Momentum
61
87
Value
41
41
Sentiment
43
11
Setup Bias
Net —
-
Market Cap
-
-
Posture
Defensive
Defensive
Open Side-by-Side ComparisonCompare all

Grade position vs URGN

PVLA / URGN
Grade Position
Below peers
PVLA vs. peer average (D vs. C)
33/100
Momentum
61
URGN
Value
41
PVLA
Sentiment
43
PVLA

Rotation landscape

Peers ranked by the order returned from the peer source, with grades from the API.

Rank
Ticker
Company
Grade
Grade score
vs PVLA
1
URGN
URGN
F
20/100
+1
2
SANA
SANA
D
40/100
Even
3
NTLA
NTLA
A
100/100
-3
4
HRMY
Harmony Biosciences Holdings Inc Common
A
100/100
-3
5
ALMR
Alamar Biosciences Inc Common
C
60/100
-1
URGN is the first peer returned for this comparison set.